



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 5 :</b>  <b>C07K 7/10, A61K 37/43</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 90/12810</b>  <b>(43) International Publication Date:</b> 1 November 1990 (01.11.90)
<b>(21) International Application Number:</b> PCT/US90/02224 <b>(22) International Filing Date:</b> 24 April 1990 (24.04.90)  <b>(30) Priority data:</b> 342,751                      25 April 1989 (25.04.89)                      US  <b>(71) Applicant:</b> THE SALK INSTITUTE FOR BIOLOGICAL STUDIES [US/US]; 10010 North Torrey Pines Road, La Jolla, CA 92037 (US).  <b>(72) Inventors:</b> RIVIER, Jean, Edouard, Frederic ; 9674 Blackgold Road, La Jolla, CA 92037 (US). VALE, Wylie, Walker, Jr. ; 1643 Valdez, La Jolla, CA 92037 (US). RIVIER, Catherine, Laure ; 9674 Blackgold Road, La Jolla, CA 92037 (US).		<b>(74) Agents:</b> WATT, Phillip, H. et al.; Fitch, Even, Tabin & Flannery, Room 900, 135 South LaSalle Street, Chicago, IL 60603 (US).  <b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> GRF ANALOGS VIIA  <b>(57) Abstract</b>  <p>The invention provides synthetic peptides which are extremely potent in stimulating the release of pituitary GH in animals, including humans and also resist enzymatic degradation in the body. The peptides have the sequence: (B)R<sub>1</sub>-R<sub>2</sub>-R<sub>3</sub>-Ala-(Q<sub>1</sub>)R<sub>5</sub>-Phe-Thr-R<sub>8</sub>-Ser-(Q<sub>2</sub>)R<sub>10</sub>-Arg-R<sub>12</sub>-(Q<sub>3</sub>)R<sub>13</sub>-Leu-R<sub>15</sub>-Gln-(Q<sub>4</sub>)Leu-R<sub>18</sub>-(Q<sub>5</sub>)Ala-Arg-R<sub>21</sub>-(Q<sub>6</sub>)R<sub>22</sub>-(Q<sub>7</sub>)Leu-R<sub>24</sub>-R<sub>25</sub>-(Q<sub>8</sub>)R<sub>26</sub>-(Q<sub>9</sub>)R<sub>27</sub>-R<sub>28</sub>-Arg-Gln-Gln-Gly-Glu-R<sub>34</sub>-Asn-Gln-Glu-R<sub>38</sub>-R<sub>39</sub>-R<sub>40</sub>-Arg-R<sub>42</sub>-R<sub>43</sub>-R<sub>44</sub> wherein R<sub>1</sub> is Tyr, D-Tyr, Met, Phe, D-Phe, pCl-Phe, Leu, His or D-His; B is H, C<sup>α</sup>Me, N<sup>α</sup>Me, desamino, Ac or For; R<sub>2</sub> is Ala, D-Ala, NMA or D-NMA; R<sub>3</sub> is Asp or D-Asp; R<sub>5</sub> is Ile or Leu; R<sub>8</sub> is Ser, Asn, Lys, Arg, Asp or Glu; R<sub>10</sub> is Tyr, D-Tyr or Phe; R<sub>12</sub> is Arg or Lys; R<sub>13</sub> is Ile, Val, Leu or Ala; R<sub>15</sub> is Gly or Ala; R<sub>18</sub> is Ser or Tyr; R<sub>21</sub> is Lys, D-Lys, Arg or D-Arg; R<sub>22</sub> is Leu, Ile, Ala or Val; R<sub>24</sub> is Gln or His; R<sub>25</sub> is Asp or Glu; R<sub>26</sub> is Ile or Leu; R<sub>27</sub> is Met, D-Met, Ala, Nle, Ile, Leu, Nva or Val; R<sub>28</sub> is Asn or Ser; R<sub>34</sub> is Ser or Arg; R<sub>38</sub> is Arg or Gln; R<sub>39</sub> is Gly or Arg; R<sub>40</sub> is Ala or Ser; R<sub>42</sub> is Phe, Ala or Val; R<sub>43</sub> is Asn or Arg; R<sub>44</sub> is a natural amino acid; Q<sub>1</sub>-Q<sub>9</sub> are either H or C<sup>α</sup>Me, provided however that one of Q<sub>1</sub>, Q<sub>4</sub>, Q<sub>7</sub>, Q<sub>8</sub> and Q<sub>9</sub> is C<sup>α</sup>Me. These peptides may also be used diagnostically, and the C-terminus can be shortened to residue-29.</p>		

### DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

#### *FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Fasso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TG	Togo
DK	Denmark			US	United States of America

- 1 -

GRF ANALOGS VIIA

The present invention relates to peptides having influence on the function of the pituitary gland in humans and other animals. In particular, the present invention is directed to peptides which promote the release of growth hormone by the pituitary gland.

BACKGROUND OF THE INVENTION

Physiologists have long recognized that the hypothalamus controls the secretory functions of the adenohypophysis with the hypothalamus producing special substances which stimulate or inhibit the secretion of each pituitary hormone. A hypothalamic inhibitory factor was characterized in 1972 in the form of somatostatin which inhibits the secretion of growth hormone (GH). In 1982, human pancreatic (tumor) releasing factors (hpGRF) were isolated from extracts of human pancreatic tumors, purified, characterized, synthesized and tested, which were found to promote the release of GH by the pituitary. Both of these hypophysiotropic factors have been reproduced by total synthesis, and analogs of the native structures have been synthesized. Human hypothalamic GH releasing factor has precisely the same structure; thus, the term hGRF is used hereinafter.

SUMMARY OF THE INVENTION

Synthetic polypeptides have now been synthesized and tested which release GH from cultured pituitary cells, which have increased resistance to enzymatic degradation in the body, and which exhibit very substantially increased potency. These advantageous properties result from the peptides having an alpha-helical form of increased stability, which peptides have at least one residue in one or more of positions 5, 17, 23, 26 and 27 that is substituted with a methyl group on its alpha carbon atom (C<sup>α</sup>Me), and preferably several

- 2 -

of these residues are so substituted. Ala having its alpha carbon atom substituted with a methyl group is indicated by the abbreviation CMA or Aib (for amino-isobutyric acid), whereas Leu having its alpha  
5 carbon atom substituted with a methyl group is indicated by CML.

In addition to the foregoing, the peptides may contain other substitutions for various residues found in the native hormones. For example, D-Ala,  $N^aCH_3$ -  
10 D-Ala(D-NMA) or NMA may be substituted in the 2-position. Either  $C^aMeLeu$ (CML) or Nle is preferably present instead of Met in the 27-position; however, D-Met or Nva or other residues may be present. The peptides may also have one of the following residues in the  
15 1-position: Tyr, D-Tyr, Met, Phe, D-Phe, pCl-Phe, Leu, His and D-His, which residue may optionally have a methyl substitution either on the alpha-carbon or in the alpha-amino group, or the alpha-amino group may be deleted (desamino); this residue may also have its  
20 alpha-amino group acylated, preferably by acetyl (Ac) or formyl (For). The peptides may optionally contain other substitutions as are known in the art, e.g., D-Asp at the 3-position and/or Arg at the 12-position and/or Phe or D-Tyr at the 10-position and/or Ala at the 15-position  
25 and/or Asn in the 28-position.

Pharmaceutical compositions in accordance with the invention include such analogs which are between about 29 and 44 residues in length, or a nontoxic salt of any of these, dispersed in a pharmaceutically or  
30 veterinarily acceptable liquid or solid carrier. Such pharmaceutical compositions can be used in clinical medicine, both human and veterinary, for administration for therapeutic purposes, and also diagnostically. Moreover, they can be used to promote the growth of warm-  
35 blooded animals, including fowl, and in aquiculture.

- 3 -

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

The nomenclature used to define the peptides is that specified by Schroder & Lubke, "The Peptides", Academic Press (1965), wherein in accordance with  
 5 conventional representation the amino group at the N-terminus appears to the left and the carboxyl group at the C-terminus to the right. By natural amino acid is meant one of common, naturally occurring amino acids found in proteins comprising Gly, Ala, Val, Leu, Ile,  
 10 Ser, Thr, Lys, Arg, Asp, Asn, Glu, Gln, Cys, Met, Phe, Tyr, Pro, Trp and His. By Nle is meant norleucine, and by Nva is meant norvaline. Where the amino acid residue has isomeric forms, it is the L-form of the amino acid that is represented unless otherwise expressly indicated.  
 15 D-NMA signifies the D-isomer of alanine wherein the alpha-amino group is substituted by methyl.

The invention generally provides synthetic peptides having the following sequence (I): (B)R<sub>1</sub>-R<sub>2</sub>-R<sub>3</sub>-Ala-(Q<sub>1</sub>)R<sub>5</sub>-Phe-Thr-R<sub>8</sub>-Ser-(Q<sub>2</sub>)R<sub>10</sub>-Arg-R<sub>12</sub>-(Q<sub>3</sub>)R<sub>13</sub>-Leu-  
 20 R<sub>15</sub>-Gln-(Q<sub>4</sub>)Leu-R<sub>18</sub>-(Q<sub>5</sub>)Ala-Arg-R<sub>21</sub>-(Q<sub>6</sub>)R<sub>22</sub>-(Q<sub>7</sub>)Leu-R<sub>24</sub>-R<sub>25</sub>-(Q<sub>8</sub>)R<sub>26</sub>-(Q<sub>9</sub>)R<sub>27</sub>-R<sub>28</sub>-Arg-Gln-Gln-Gly-Glu-R<sub>34</sub>-Asn-Gln-Glu-R<sub>38</sub>-R<sub>39</sub>-R<sub>40</sub>-Arg-R<sub>42</sub>-R<sub>43</sub>-R<sub>44</sub> wherein R<sub>1</sub> is Tyr, D-Tyr, Met, Phe, D-Phe, pCl-Phe, Leu, His or D-His; B is H, C<sup>a</sup>Me, N<sup>a</sup>Me, desamino, Ac or For; R<sub>2</sub> is Ala,  
 25 D-Ala, NMA or D-NMA; R<sub>3</sub> is Asp or D-Asp; R<sub>5</sub> is Ile or Leu; R<sub>8</sub> is Ser, Asn, Lys, Arg, Asp or Glu; R<sub>10</sub> is Tyr, D-Tyr or Phe; R<sub>12</sub> is Arg or Lys; R<sub>13</sub> is Ile, Val, Leu or Ala; R<sub>15</sub> is Gly or Ala; R<sub>18</sub> is Ser or Tyr; R<sub>21</sub> is Lys, D-Lys, Arg or D-Arg; R<sub>22</sub> is Leu,  
 30 Ile, Ala or Val; R<sub>24</sub> is Gln or His; R<sub>25</sub> is Asp or Glu; R<sub>26</sub> is Ile or Leu; R<sub>27</sub> is Met, D-Met, Ala, Nle, Ile, Leu, Nva or Val; R<sub>28</sub> is Asn or Ser; R<sub>34</sub> is Ser or Arg; R<sub>38</sub> is Arg or Gln; R<sub>39</sub> is Gly or Arg; R<sub>40</sub> is Ala or Ser; R<sub>42</sub> is Phe, Ala or Val; R<sub>43</sub> is Asn or  
 35 Arg; R<sub>44</sub> is a natural amino acid; Q<sub>1</sub>-Q<sub>9</sub> are either H or C<sup>a</sup>Me, provided however that all of the residues

- 4 -

between R<sub>30</sub> and R<sub>44</sub>, inclusive, or any sequence thereof may be deleted, beginning at the C-terminus, and provided further that at least one of Q<sub>1</sub>, Q<sub>4</sub>, Q<sub>7</sub>, Q<sub>8</sub> and Q<sub>9</sub> is C<sup>a</sup>Me. In one preferred subclass of the foregoing, R<sub>5</sub> is Ile, R<sub>18</sub> is Ser, R<sub>24</sub> is Gln, R<sub>25</sub> is Asp, R<sub>26</sub> is Ile, R<sub>34</sub> is Ser, R<sub>38</sub> is Arg, R<sub>39</sub> is Gly and R<sub>40</sub> is Ala. If the peptide extends to position-44, R<sub>44</sub> is preferably Leu or Val.

Another preferred subclass is the peptides having the following sequence:

(B)R<sub>1</sub>-R<sub>2</sub>-R<sub>3</sub>-Ala-(Q<sub>1</sub>)Ile-Phe-Thr-R<sub>8</sub>-Ser-(Q<sub>2</sub>)R<sub>10</sub>-Arg-R<sub>12</sub>-(Q<sub>3</sub>)R<sub>13</sub>-Leu-R<sub>15</sub>-Gln-(Q<sub>4</sub>)Leu-Ser-(Q<sub>5</sub>)Ala-Arg-R<sub>21</sub>-(Q<sub>6</sub>)R<sub>22</sub>-(Q<sub>7</sub>)Leu-Gln-Asp-(Q<sub>8</sub>)Ile-(Q<sub>9</sub>)R<sub>27</sub>-R<sub>28</sub>-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-R<sub>42</sub>-R<sub>43</sub>-R<sub>44</sub> wherein R<sub>1</sub> is Tyr, D-Tyr, Met, Phe, D-Phe, pCl-Phe, Leu, His or D-His; B is H, C<sup>a</sup>Me, N<sup>a</sup>Me, desamino, Ac or For; R<sub>2</sub> is Ala, D-Ala, NMA or D-NMA; R<sub>3</sub> is Asp or D-Asp; R<sub>8</sub> is Ser, Asn, Lys, Arg, Asp or Gln; R<sub>10</sub> is Tyr, D-Tyr or Phe; R<sub>12</sub> is Arg or Lys; R<sub>13</sub> is Ile, Val, Leu or Ala; R<sub>15</sub> is Gly or Ala; R<sub>21</sub> is Lys, D-Lys, Arg or D-Arg; R<sub>22</sub> is Leu, Ile, Ala or Val; R<sub>27</sub> is Met, D-Met, Ala, Nle, Ile, Leu, Nva or Val; R<sub>28</sub> is Asn or Ser; R<sub>42</sub> is Phe, Ala or Val; R<sub>43</sub> is Asn or Arg; R<sub>44</sub> is a natural amino acid; Q<sub>1</sub>-Q<sub>9</sub> are either H or C<sup>a</sup>Me, provided however that any or all of the residues between R<sub>30</sub> and R<sub>44</sub>, inclusive, may be deleted in sequence beginning at the C-terminus and provided that at least one of Q<sub>1</sub>, Q<sub>4</sub>, Q<sub>7</sub>, Q<sub>8</sub> and Q<sub>9</sub> is C<sup>a</sup>Me. In any of these peptides, the carboxyl moiety of the amino acid residue at the C-terminus may be any of the following radicals:

-COOR, -CRO, -CONHNHR, -CON(R)(R') or -CH<sub>2</sub>OR, with R and R' being lower alkyl, fluoro lower alkyl or hydrogen; methyl, ethyl and propyl are the preferred lower alkyl groups. Preferably it is -CONHR, with R being H or lower alkyl.

- 5 -

Still another preferred subclass of peptides provided by the invention are those according to the formula:

5 (B)R<sub>1</sub>-R<sub>2</sub>-Asp-Ala-(Q<sub>1</sub>)Ile-Phe-Thr-R<sub>8</sub>-Ser-(Q<sub>2</sub>)R<sub>10</sub>-Arg-R<sub>12</sub>-  
(Q<sub>3</sub>)R<sub>13</sub>-Leu-R<sub>15</sub>-Gln-(Q<sub>4</sub>)Leu-R<sub>18</sub>-(Q<sub>5</sub>)Ala-Arg-R<sub>21</sub>-(Q<sub>6</sub>)R<sub>22</sub>-  
(Q<sub>7</sub>)Leu-R<sub>24</sub>-R<sub>25</sub>-(Q<sub>8</sub>)R<sub>26</sub>-(Q<sub>9</sub>)R<sub>27</sub>-R<sub>28</sub>-Arg-Gln-Gln-Gly-Y  
wherein R<sub>1</sub> is Tyr, D-Tyr, Phe, D-Phe, His or D-His;  
B is H, C<sup>a</sup>Me or N<sup>a</sup>Me; R<sub>2</sub> is Ala, D-Ala, NMA or  
D-NMA; R<sub>8</sub> is Ser, Asn, Lys, Arg, Asp or Glu; R<sub>10</sub> is  
10 Tyr, D-Tyr or Phe; R<sub>12</sub> is Arg or Lys; R<sub>13</sub> is Ile,  
Val, Leu or Ala; R<sub>15</sub> is Gly or Ala; R<sub>18</sub> is Ser or  
Tyr; R<sub>21</sub> is Lys, D-Lys, Arg or D-Arg; R<sub>22</sub> is Leu,  
Ile, Ala or Val; R<sub>24</sub> is Gln or His; R<sub>25</sub> is Asp or  
Glu; R<sub>27</sub> is Met, Ala, Nle, Ile, Leu, Nva or Val; R<sub>28</sub>  
15 is Asn or Ser; Y is NHR with R being H or lower alkyl;  
Q<sub>1</sub>-Q<sub>9</sub> are either H or C<sup>a</sup>Me, provided however that  
Gly, Gln-Gly or Gln-Gln-Gly may be deleted at the  
C-terminus, and provided also that at least one of Q<sub>1</sub>,  
Q<sub>4</sub>, Q<sub>7</sub>, Q<sub>8</sub> and Q<sub>9</sub> is C<sup>a</sup>Me.

20 As defined above, fragments which extend from  
the N-terminus through residue-29 have biological potency  
in effecting the release of GH by the pituitary, and such  
biologically active fragments of 29 or 32 residues in  
length which have a C-terminus that is an amide or a  
25 substituted amide are most preferred. When the peptide  
has 40 or more residues, there is no clear preference for  
the moiety at the C-terminus.

The peptides are synthesized by a suitable  
method, such as by exclusively solid-phase techniques, by  
30 partial solid-phase techniques, by fragment condensation  
or by solution couplings. For example, techniques of  
exclusively solid-phase synthesis are set forth in the  
textbook "Solid-Phase Peptide Synthesis", Stewart &  
Young, Freeman & Co., San Francisco, 1969, and are  
35 exemplified by the disclosure of U.S. Patent No.  
4,105,603, issued August 8, 1978 to Vale et al. Solution  
synthesis is described in detail in the treatise

- 6 -

"Methoden der Organischen Chemie (Houben-Weyl): Synthese von Peptiden", E. Wunsch (editor) (1974) Georg Thieme Verlag, Stuttgart, W. Ger. The fragment condensation method of synthesis is exemplified in U.S. Patent No. 3,972,859 (August 3, 1976). Other available syntheses are exemplified by U.S. Patent No. 3,842,067 (October 15, 1974) and U.S. Patent No. 3,862,925 (January 28, 1975).

Common to such syntheses is the protection of the labile side chain groups of the various amino acid moieties with suitable protecting groups which will prevent a chemical reaction from occurring at that site until the group is ultimately removed. Usually also common is the protection of an alpha-amino group on an amino acid or a fragment while that entity reacts at the carboxyl group, followed by the selective removal of the alpha-amino protecting group to allow subsequent reaction to take place at that location. Accordingly, it is common that, as a step in the synthesis, an intermediate compound is produced which includes each of the amino acid residues located in its desired sequence in the peptide chain with side-chain protecting groups linked to the appropriate residues.

In this respect, the present invention creates intermediates of the Formula (II):  $X^1-(B)R_1(X \text{ or } X^2)-R_2-R_3(X^3)-\text{Ala}-(Q_1)R_5-\text{Phe}-\text{Thr}(X^4)-R_8(X^8)-\text{Ser}(X^4)-(Q_2)R_{10}(X^2)-\text{Arg}(X^6)-R_{12}(X^6 \text{ or } X^7)-(Q_3)R_{13}-\text{Leu}-R_{15}-\text{Gln}(X^5)-(Q_4)\text{Leu}-R_{18}(X^2 \text{ or } X^4)-(Q_5)\text{Ala}-\text{Arg}(X^6)-R_{21}(X^6 \text{ or } X^7)-(Q_6)R_{22}-(Q_7)\text{Leu}-R_{24}(X^5 \text{ or } X)-R_{25}(X^3)-(Q_8)R_{26}-(Q_9)R_{27}-R_{28}(X^4 \text{ or } X^5)-\text{Arg}(X^6)-\text{Gln}(X^5)-\text{Gln}(X^5)-\text{Gly}-\text{Glu}(X^3)-R_{34}(X^4 \text{ or } X^6)-\text{Asn}(X^5)-\text{Gln}(X^5)-\text{Glu}(X^3)-R_{38}(X^6 \text{ or } X^5)-R_{39}(X^6)-R_{40}(X^2)-\text{Arg}(X^6)-R_{42}-R_{43}(X^5 \text{ or } X^6)-R_{44}(X^8)-X^9$  wherein:  $X^1$  is either hydrogen or an alpha-amino protecting group. The alpha-amino protecting groups contemplated by  $X^1$  are those well known to be useful in the art of stepwise synthesis of polypeptides. Among the classes of alpha-amino protecting groups which may be employed as



- 7 -

$x^1$  are (1) aromatic urethan-type protecting groups, such as fluorenylmethyloxycarbonyl (Fmoc), benzyloxycarbonyl(Z) and substituted Z, such as p-chlorobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, and p-methoxybenzyloxycarbonyl; (2) aliphatic urethan protecting groups, such as t-butyloxycarbonyl (BOC), diisopropylmethyloxycarbonyl, isopropylloxycarbonyl, ethoxycarbonyl, allyloxycarbonyl; and (3) cycloalkyl urethan-type protecting groups, such as cyclopentylloxycarbonyl, adamantylloxycarbonyl, and cyclohexylloxycarbonyl. The preferred alpha-amino protecting group is BOC, even when an  $N^a$ Me-substituted residue is employed in the 1-position; of course  $x^1$  is H when B is desamino.

$x$  is hydrogen or a protecting group for the imidazole nitrogen of His, such as Tos.

$x^2$  may be a suitable protecting group for the phenolic hydroxyl group of Tyr, such as tetrahydropyranyl, tert-butyl, trityl, Bzl, CBZ, 4Br-CBZ and 2,6-dichlorobenzyl(DCB). The preferred protecting group is 2,6-dichlorobenzyl.  $x^2$  can be hydrogen which means that there is no side-chain protecting group on the amino acid residue in that position.

$x^3$  is hydrogen or a suitable ester-forming protecting group for the carboxyl group of Asp or Glu, such as benzyl(OBzl), 2,6-dichlorobenzyl, methyl and ethyl.

$x^4$  may be a suitable protecting group for the hydroxyl group of Thr or Ser, such as acetyl, benzoyl, tert-butyl, trityl, tetrahydropyranyl, Bzl, 2,6-dichlorobenzyl and CBZ. The preferred protecting group is Bzl.  $x^4$  can be hydrogen, which means there is no protecting group on the hydroxyl group.

$x^5$  is hydrogen or a suitable protecting group for the side chain amido group of Asn or Gln. It is preferably xanthyl(Xan).

- 8 -

$x^6$  is a suitable protecting group for the guanido group of Arg, such as nitro, Tos, CBZ, adamantyloxycarbonyl, and BOC, or is hydrogen.

5  $x^7$  is hydrogen or a suitable protecting group for the side chain amino group of Lys. Illustrative of suitable side chain amino protecting groups are 2-chlorobenzoyloxycarbonyl(2-Cl-Z), Tos, t-amylloxycarbonyl and BOC.

10  $x^8$  is hydrogen or a suitable side-chain protecting group as generally specified above.

Met can optionally be protected by oxygen, but is preferably left unprotected.

15 The selection of a side chain amino protecting group is not critical except that generally one is chosen which is not removed during deprotection of the alpha-amino groups during the synthesis. However, for some amino acids, e.g. His, protection is not generally necessary after coupling is completed, and the protecting groups may be the same.

20  $x^9$  is a suitable protecting group for the C-terminal carboxyl group, such as the ester-forming group  $x^3$ , or is an anchoring bond used in solid-phase synthesis for linking to a solid resin support, or is des- $x^9$ , in which case the residue at the C-terminus has  
25 a carboxyl moiety which is Y, as defined herein-before. When a solid resin support is used, it may be any of those known in the art, such as one having the formulae: -O-CH<sub>2</sub>-resin support, -NH-benzhydrylamine (BHA) resin support or -NH-paramethylbenzhydrylamine (MBHA) resin  
30 support. When the unsubstituted amide is desired, use of BHA or MBHA resin is preferred, because cleavage directly gives the amide. In case the N-methyl amide is desired, it can be generated from an N-methyl BHA resin. Should other substituted amides be desired, the teaching of U.S.  
35 Patent No. 4,569,967 can be used, or should still other groups than the free acid be desired at the C-terminus, it may be preferable to synthesize the peptide using

- 9 -

solution synthesis methods as set forth in the Houben-Weyl text.

In the formula for the intermediate, at least one of the X-groups is a protecting group or X<sup>9</sup> includes resin support. Thus, the invention also provides a method for manufacturing a peptide of interest by (a) forming a peptide having at least one protective group and the formula (II): wherein: X, X<sup>1</sup>, X<sup>2</sup>, X<sup>3</sup>, X<sup>4</sup>, X<sup>5</sup>, X<sup>6</sup>, X<sup>7</sup> and X<sup>8</sup> are each either hydrogen or a protective group and X<sup>9</sup> is either a protective group or an anchoring bond to resin support or is des-X<sup>9</sup>, in which case the residue at the C-terminus may have the desired carboxy moiety; (b) splitting off the protective group or groups or anchoring bond from the peptide of the formula (II); and (c) if desired, converting the resulting peptide of the sequence (I) into a nontoxic salt thereof.

In selecting a particular side chain protecting group to be used in the synthesis of the peptides, the following general rules are followed: (a) the protecting group preferably retains its protecting properties and is not be split off under coupling conditions, (b) the protecting group should be stable to the reagent and, with the exception of Xan, is preferably stable under the reaction conditions selected for removing the alpha-amino protecting group at each step of the synthesis, and (c) the side chain protecting group must be removable, upon the completion of the synthesis containing the desired amino acid sequence, under reaction conditions that will not undesirably alter the peptide chain.

The peptides are preferably prepared using solid phase synthesis, such as that generally described by Merrifield, J. Am. Chem. Soc., 85, p 2149 (1963), although other equivalent chemical syntheses known in the art can also be used as previously mentioned. Solid-phase synthesis is commenced from the C-terminus of the peptide by coupling a protected alpha-amino acid to a

- 10 -

suitable resin. Such a starting material can be prepared by attaching an alpha-amino-protected amino acid by an ester linkage to a chloromethylated resin or a hydroxymethyl resin, or by an amide bond to a BHA resin or MBHA resin. The preparation of the hydroxymethyl resin is described by Bodansky et al., Chem. Ind. (London) 38, 1597-98 (1966). Chloromethylated resins are commercially available from Bio Rad Laboratories, Richmond, California and from Lab. Systems, Inc. The preparation of such a resin is described by Stewart et al., "Solid Phase Peptide Synthesis" (Freeman & Co., San Francisco 1969), Chapter 1, pp 1-6. BHA and MBHA resin supports are commercially available and are generally used only when the desired polypeptide being synthesized has an unsubstituted amide at the C-terminal.

The C-terminal amino acid, e.g. Asn, protected by BOC and by Xan, can be first coupled to the chloromethylated resin according to the procedure set forth in Chemistry Letters, K. Horiki et al. 165-168 (1978); using KF in DMF at about 60°C. for 24 hours with stirring, when for example a 43-residue free acid analog of rat GRF(rGRF) is to be synthesized. Following the coupling of the BOC-protected amino acid to the resin support, the alpha-amino protecting group is removed, as by using trifluoroacetic acid(TFA) in methylene chloride or TFA alone. The deprotection is carried out at a temperature between about 0°C. and room temperature. Other standard cleaving reagents, such as HCl in dioxane, and conditions for removal of specific alpha-amino protecting groups may be used as described in Schroder & Lubke, "The Peptides", 1, pp 72-75 (Academic Press 1965).

After removal of the alpha-amino protecting group, the remaining alpha-amino- and side-chain-protected amino acids are coupled stepwise in the desired order to obtain the intermediate compound defined hereinbefore, or as an alternative to adding each amino acid separately in the synthesis, some of them may

- 11 -

be coupled to one another prior to addition to the solid phase reactor. The selection of an appropriate coupling reagent is within the skill of the art. Particularly suitable as a coupling reagent is N,N'-dicyclohexyl carbodiimide (DCCI).

The activating reagents used in the solid phase synthesis of the peptides are well known in the peptide art. Examples of suitable activating reagents are carbodiimides, such as N,N'-diisopropylcarbodiimide and N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide. Other activating reagents and their use in peptide coupling are described by Schroder & Lubke supra, in Chapter III and by Kapoor, J. Phar. Sci., 59, pp 1-27 (1970).

Each protected amino acid or amino acid sequence is introduced into the solid phase reactor in about a fourfold or more excess, and the coupling may be carried out in a medium of dimethylformamide(DMF):CH<sub>2</sub>Cl<sub>2</sub> (1:1) or in DMF or CH<sub>2</sub>Cl<sub>2</sub> alone. In cases where incomplete coupling occurs, the coupling procedure is repeated before removal of the alpha-amino protecting group prior to the coupling of the next amino acid. The success of the coupling reaction at each stage of the synthesis, if performed manually, is preferably monitored by the ninhydrin reaction, as described by E. Kaiser et al., Anal. Biochem. 34, 595 (1970). The coupling reactions can be performed automatically, as on a Beckman 990 automatic synthesizer, using a program such as that reported in Rivier et al. Biopolymers, 1978, 17, pp 1927-1938.

After the desired amino acid sequence has been completed, the intermediate peptide can be removed from the resin support by treatment with a reagent, such as liquid hydrogen fluoride, which not only cleaves the peptide from the resin but also cleaves all remaining side chain protecting groups X, X<sup>2</sup>, X<sup>3</sup>, X<sup>4</sup>, X<sup>5</sup>, X<sup>6</sup>, X<sup>7</sup> and X<sup>8</sup> and the anchoring bond X<sup>9</sup> and also the alpha-amino protecting group X<sup>1</sup> if one is used, to

- 12 -

obtain the peptide in the form of the free acid. If Met is present in the sequence, the BOC protecting group is preferably first removed using trifluoroacetic acid(TFA)/ethanedithiol prior to cleaving the peptide from the resin with HF to eliminate potential S-alkylation. When using hydrogen fluoride for cleaving, anisole and methylethyl sulfide are included as scavengers in the reaction vessel.

The following Example 1 sets forth a preferred method for synthesizing peptides by the solid-phase technique. It will of course be appreciated that the synthesis of a correspondingly longer peptide is effected in the same manner by merely adding the requisite number of amino acids at the C-terminus of the chain. It is presently felt that biologically active fragments should contain the indicated sequence at the N-terminus, and addition of residues to the N-terminus is not considered advantageous.

#### EXAMPLE 1

The synthesis of the peptide [ $N^a$ MeTyr<sup>1</sup>, Ala<sup>15</sup>, CML<sup>27</sup>, Asn<sup>28</sup>]-hGRF(1-29)-NH<sub>2</sub> having the formula:  $N^a$ MeTyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-CML-Asn-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 peptide synthesizer on a commercially available MBHA resin as generally described in Vale et al. U.S. Patent No. 4,292,313. Coupling of BOC-Arg(Tos) to the resin results in the substitution of about 0.35 mmol. Arg per gram of resin.

After deblocking and neutralization, the peptide chain is built step-by-step on the resin. Deblocking, neutralization and addition of each amino acid is performed in general accordance with the procedure set forth in detail in Rivier, J., J. Amer. Chem. Soc., 96, 2986-2992 (1974). All solvents that are used are carefully degassed by sparging with an inert gas, e.g.

- 13 -

helium or nitrogen, to insure the absence of oxygen that might undesirably oxidize the sulfur of the Met residue.

Deblocking is preferably carried out in accordance with Schedule A which follows:

5

SCHEDULE A

	<u>Reagent</u>	<u>Mixing time (Min.)</u>
	1. 60% TFA/2% ethanedithiol	10
	2. 60% TFA/2% ethanedithiol	15
	3. IPA/1% ethanedithiol	0.5
10	4. Et <sub>3</sub> N (10%) in CH <sub>2</sub> Cl <sub>2</sub>	0.5
	5. MeOH	0.5
	6. Et <sub>3</sub> N (10%) in CH <sub>2</sub> Cl <sub>2</sub>	0.5
	7. MeOH (twice)	0.5
	8. CH <sub>2</sub> Cl <sub>2</sub> (twice)	0.5

15

The couplings are preferably carried out as set out in Schedule B which follows:

SCHEDULE B

	<u>Reagent</u>	<u>Mixing time (Min.)</u>
20	9. DCCI	-
	10. Boc-amino acid	50-90
	11. MeOH (twice)	0.5
	12. CH <sub>2</sub> Cl <sub>2</sub> (twice)	0.5
	13. Ac <sub>2</sub> O (3M) in CH <sub>2</sub> Cl <sub>2</sub>	15.0
25	14. CH <sub>2</sub> Cl <sub>2</sub>	0.5
	15. MeOH	0.5
	16. CH <sub>2</sub> Cl <sub>2</sub> (twice)	0.5

30

Briefly, one to two mmol. of BOC-protected amino acid in methylene chloride is used per gram of resin, plus one equivalent of 1.0 molar DCCI in methylene chloride for two hours. When BOC-Arg(Tos) is being coupled, a mixture of 50% DMF and methylene chloride is used. Bzl ether is used as the hydroxyl side-chain protecting group for Ser and Thr. The amido group of Asn or Gln is protected by Xan when DCC coupling is used as is preferred. P-nitrophenyl ester(ONp) may also be used to activate the carboxyl end of Asn or Gln, and for

35

- 14 -

example, BOC-Asn(ONp) can be coupled overnight using one equivalent of HOBt in a 50% mixture of DMF and methylene chloride, in which case no DCC is added.

2-chloro-benzyloxycarbonyl(2Cl-Z) is used as the  
5 protecting group for the Lys side chain. Tos is used to protect the guanido group of Arg and the imidazole nitrogen of His, and the Glu or Asp side-chain carboxyl group is protected with OBzl. The phenolic hydroxyl group of Tyr is protected with 2,6-dichloro-  
10 benzyl(DCB). At the end of the synthesis, the following composition is obtained:

BOC-N<sup>a</sup>MeTyr(X<sup>2</sup>)-Ala-Asp(X<sup>3</sup>)-Ala-Ile-Phe-Thr(X<sup>4</sup>)-Asn(X<sup>5</sup>)-  
Ser(X<sup>4</sup>)-Tyr(X<sup>2</sup>)-Arg(X<sup>6</sup>)-Lys(X<sup>7</sup>)-Val-Leu-Ala-Gln(X<sup>5</sup>)-  
15 Leu-Ser(X<sup>4</sup>)-Ala-Arg(X<sup>6</sup>)-Lys(X<sup>7</sup>)-Leu-Leu-Gln(X<sup>5</sup>)-Asp(X<sup>3</sup>)-  
Ile-CML-Asn(X<sup>5</sup>)-Arg(X<sup>6</sup>)-X<sup>9</sup> wherein X<sup>2</sup> is DCB,  
X<sup>3</sup> is OBzl, X<sup>4</sup> is Bzl, X<sup>5</sup> is Xan, X<sup>6</sup> is Tos, X<sup>7</sup>  
is 2Cl-Z and X<sup>9</sup> is NH-MBHA-resin support. Xan may have been partially or totally removed by TFA treatment used to deblock the alpha-amino protecting group.

20 In order to cleave and deprotect the protected peptide-resin, it is treated with 1.5 ml. anisole, 0.5 ml. methylethylsulfide and 15 ml. hydrogen fluoride(HF) per gram of peptide-resin, at -20°C. for one-half hour and at 0°C. for one-half hour. After elimination of the  
25 HF under high vacuum, the resin-peptide remainder is washed alternately with dry diethyl ether and chloroform, and the peptide is then extracted with degassed 2N aqueous acetic acid and separated from the resin by filtration.

30 The cleaved and deprotected peptide is then dissolved in 0-5% acetic acid and subjected to purification which may include Sephadex G-50 fine gel filtration.

35 The peptide is then further purified by preparative or semi-preparative HPLC as described in Rivier et al., Peptides: Structure and Biological Function, (1979) pp 125-8 and Marki et al. J. Am. Chem.



- 15 -

Soc. 103, 3178 (1981). Cartridges fitting Waters Associates prep LC-500 are packed with 15-20 $\mu$  C<sub>18</sub> Silica from Vydac (300A). A gradient of CH<sub>3</sub>CN in TEAP is generated by a low pressure Eldex gradient maker, as  
5 described in Rivier, J., J. Liq. Chromatography 1, 343-367 (1978). The chromatographic fractions are carefully monitored by HPLC, and only the fractions showing substantial purity are pooled. Desalting of the purified fractions, independently checked for purity, is  
10 achieved using a gradient of CH<sub>3</sub>CN in 0.1% TFA. The center cut is then lyophilized to yield the desired peptide, the purity of which should be greater than 98%.

The optical rotation of the purified peptide is measured using a Perkin-Elmer polarimeter and found to be  
15  $[\alpha]_D = -52.0^\circ \pm 1$  (c = 1, 1% acetic acid).

#### EXAMPLE 2

The synthesis of a 40-residue amidated peptide [C<sup>a</sup>MeHis<sup>1</sup>, D-NMA<sup>2</sup>, CML<sup>27</sup>]-hGRF(1-40)-NH<sub>2</sub> having the formula: H-C<sup>a</sup>MeHis-D-NMA-Asp-Ala-Ile-Phe-Thr-Asn-  
20 Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-CML-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as generally described in Vale et al. U.S. Patent No.  
25 4,292,313. The peptide is judged to be substantially pure using TLC and HPLC.

#### EXAMPLE 3

The synthesis of [D-NMA<sup>2</sup>, CML<sup>27</sup>]-rGRF(1-43)-OH having the formula: H-His-D-NMA-Asp-Ala-Ile-Phe-Thr-Ser-  
30 Ser-Tyr-Arg-Arg-Ile-Leu-Gly-Gln-Leu-Tyr-Ala-Arg-Lys-Leu-Leu-His-Glu-Ile-CML-Asn-Arg-Gln-Gln-Gly-Glu-Arg-Asn-Gln-Glu-Gln-Arg-Ser-Arg-Phe-Asn-OH is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer, using a chloromethylated resin with initial coupling as described  
35 in Chemistry Letters, supra, and thereafter in the manner generally described in Example 1. The peptide is judged to be substantially pure using TLC and HPLC.

- 16 -

EXAMPLE 4

The synthesis of the hGRF analog fragment, [N<sup>a</sup>MeTyr<sup>1</sup>, Lys<sup>8</sup>, Ala<sup>15</sup>, CML<sup>27</sup>, Asn<sup>28</sup>]-hGRF(1-29)-NH<sub>2</sub> having the formula: N<sup>a</sup>MeTyr-Ala-Asp-Ala-Ile-  
5 Phe-Thr-Lys-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-CML-Asn-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as in Example 1. This analog is judged to be substantially pure using TLC  
10 and HPLC.

The synthesis is repeated changing the N-terminal residue to produce [N<sup>a</sup>MeHis<sup>1</sup>, Lys<sup>8</sup>, Ala<sup>15</sup>, CML<sup>27</sup>, Asn<sup>28</sup>]-hGRF(1-29)-NH<sub>2</sub>

EXAMPLE 5

15 The synthesis of the hGRF analog fragment [N<sup>a</sup>MeTyr<sup>1</sup>, D-Lys<sup>21</sup>, CML<sup>27</sup>]-hGRF(1-29)-NH<sub>2</sub> having the formula: N<sup>a</sup>MeTyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-D-Lys-Leu-Leu-Gln-Asp-Ile-CML-Ser-Arg-NH<sub>2</sub> is conducted in a stepwise  
20 manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as in Example 1. The peptide is judged to be substantially pure using TLC and HPLC.

EXAMPLE 6

25 The synthesis of [N<sup>a</sup>MeHis<sup>1</sup>, D-NMA<sup>2</sup>, Lys<sup>8</sup>, D-Arg<sup>21</sup>, CML<sup>27</sup>]-rGRF(1-29)-NH<sub>2</sub>, having the formula: N<sup>a</sup>Me-His-D-NMA-Asp-Ala-Ile-Phe-Thr-Lys-Ser-Tyr-Arg-Arg-Ile-Leu-Gly-Gln-Leu-Tyr-Ala-Arg-D-Arg-Leu-Leu-His-Glu-Ile-CML-Asn-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin  
30 as in Example 1. The peptide is judged to be substantially pure using TLC and HPLC.

EXAMPLE 7

35 The synthesis of [N<sup>a</sup>MeTyr<sup>1</sup>, C<sup>a</sup>Me-D-Tyr<sup>10</sup>, D-Lys<sup>21</sup>, CML<sup>27</sup>]-hGRF(1-29)-NH<sub>2</sub> having the formula: N<sup>a</sup>MeTyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-C<sup>a</sup>Me-D-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-D-Lys-Leu-Leu-Gln-Asp-Ile-CML-Ser-Arg-NH<sub>2</sub> is conducted in a stepwise

- 17 -

manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as in Example 1. The peptide is judged to be substantially pure using TLC and HPLC.

EXAMPLE 8

5           The synthesis of [D-NMA<sup>2</sup>, CML<sup>5</sup>, D-Lys<sup>21</sup>, Nva<sup>27</sup>]-rGRF(1-29)-NH<sub>2</sub> having the formula: H-His-D-NMA-Asp-Ala-CML-Phe-Thr-Asn-Ser-Tyr-Arg-Arg-Ile-Leu-Gly-Gln-Leu-Tyr-Ala-Arg-D-Lys-Leu-Leu-His-Glu-Ile-Nva-Asn-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman  
10 990 Peptide Synthesizer on an MBHA resin as in Example 1. The peptide is judged to be substantially pure using TLC and HPLC.

EXAMPLE 9

15           The synthesis of [D-Phe<sup>1</sup>, D-NMA<sup>2</sup>, Glu<sup>8</sup>, C<sup>a</sup>MeTyr<sup>10</sup>, Ile<sup>13</sup>, CML<sup>23</sup>]-hGRF(1-32)-NH<sub>2</sub> having the formula:  
H-D-Phe-D-NMA-Asp-Ala-Ile-Phe-Thr-Glu-Ser-C<sup>a</sup>MeTyr-Arg-Lys-Ile-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-CML-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-NH<sub>2</sub> is conducted in a  
20 stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as generally described in Vale et al. U.S. Patent No. 4,292,313. The peptide is judged to be substantially pure using TLC and HPLC.

EXAMPLE 10

25           The synthesis of [N<sup>a</sup>MeHis<sup>1</sup>, D-NMA<sup>2</sup>, C<sup>a</sup>MeVal<sup>13</sup>-CML<sup>27</sup>]-hGRF(1-29)-NH<sub>2</sub> having the formula: N<sup>a</sup>MeHis-D-NMA-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-C<sup>a</sup>MeVal-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-CML-Ser-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a  
30 Beckman 990 Peptide Synthesizer on an MBHA resin as generally described in Vale et al. U.S. Patent No. 4,292,313. The peptide is judged to be substantially pure using TLC and HPLC.

EXAMPLE 11

35           The synthesis of the hGRF analog fragment, [For-Tyr<sup>1</sup>, D-NMA<sup>2</sup>, C<sup>a</sup>MeTyr<sup>10</sup>, CMA<sup>19</sup>, CML<sup>27</sup>, Asn<sup>28</sup>]-hGRF(1-32)-NH<sub>2</sub> having the formula:

- 18 -

For-Tyr-D-NMA-Asp-Ala-Ile-Phe-Thr-Asn-Ser-C<sup>a</sup>MeTyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-CMA-Arg-Lys-Leu-Leu-Gln-Asp-Ile-CML-Asn-Arg-Gln-Gln-Gly-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as in Example 1. This analog is judged to be substantially pure using TLC and HPLC.

#### EXAMPLE 12

The synthesis of [D-NMA<sup>2</sup>, Lys<sup>12</sup>, C<sup>a</sup>MeIle<sup>13</sup>, CMA<sup>19</sup>, CML<sup>27</sup>]-rGRF(1-29)-NH<sub>2</sub>, having the formula: H-His-D-NMA-Asp-Ala-Ile-Phe-Thr-Ser-Ser-Tyr-Arg-Lys-C<sup>a</sup>MeIle-Leu-Gly-Gln-Leu-Tyr-CMA-Arg-Lys-Leu-Leu-His-Glu-Ile-CML-Asn-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as in Example 1. The peptide is judged to be substantially pure using TLC and HPLC.

#### EXAMPLE 13

The synthesis of the hGRF analog fragment [D-NMA<sup>2</sup>, Arg<sup>12</sup>, CML<sup>23</sup>, Ile<sup>27</sup>]-hGRF(1-29)-NH<sub>2</sub> having the formula: H-Tyr-D-NMA-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Arg-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-CML-Gln-Asp-Ile-Ile-Ser-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as in Example 1. The peptide is judged to be substantially pure using TLC and HPLC.

#### EXAMPLE 14

The synthesis of [D-Phe<sup>1</sup>, D-NMA<sup>2</sup>, C<sup>a</sup>MeVal<sup>13</sup>, Ala<sup>15</sup>, CML<sup>23</sup>, D-Met<sup>27</sup>]-hGRF(1-29)-NH<sub>2</sub> having the formula: H-D-Phe-D-NMA-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-C<sup>a</sup>MeVal-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-CML-Gln-Asp-Ile-D-Met-Ser-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as in Example 1. This analog is judged to be substantially pure using TLC and HPLC.

- 19 -

EXAMPLE 15

The synthesis of [D-NMA<sup>2</sup>, D-Arg<sup>21</sup>, CML<sup>23</sup>]-hGRF(1-32)-NH<sub>2</sub> having the formula: H-Tyr-D-NMA-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-D-Arg-Leu-CML-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as in Example 1. This analog is judged to be substantially pure using TLC and HPLC.

EXAMPLE 16

The synthesis of [desaminoHis<sup>1</sup>, D-NMA<sup>2</sup>, Lys<sup>8</sup>, Asp<sup>25</sup>, CML<sup>26</sup>]-rGRF(1-29)-NH<sub>2</sub> having the formula: desNH<sub>2</sub>His-D-NMA-Asp-Ala-Ile-Phe-Thr-Lys-Ser-Tyr-Arg-Arg-Ile-Leu-Gly-Gln-Leu-Tyr-Ala-Arg-Lys-Leu-Leu-His-Asp-CML-Met-Asn-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as in Example 1. The peptide is judged to be substantially pure using TLC and HPLC.

EXAMPLE 17

The synthesis of [Ac-D-His<sup>1</sup>, D-NMA<sup>2</sup>, Arg<sup>8</sup>, C<sup>a</sup>MeTyr<sup>10</sup>, CMA<sup>13</sup>, CML<sup>27</sup>]-rGRF(1-29)-NH<sub>2</sub> having the formula: Ac-D-His-D-NMA-Asp-Ala-Ile-Phe-Thr-Arg-Ser-C<sup>a</sup>MeTyr-Arg-Arg-CMA-Leu-Gly-Gln-Leu-Tyr-Ala-Arg-Lys-Leu-Leu-His-Glu-Ile-CML-Asn-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin, in the manner generally described in Example 1. The peptide is judged to be substantially pure using TLC and HPLC.

EXAMPLE 18

The synthesis of [D-Ala<sup>2</sup>, D-Asp<sup>3</sup>, C<sup>a</sup>MeTyr<sup>10</sup>, CMA<sup>19</sup>, CML<sup>23</sup>, CML<sup>27</sup>]-hGRF(1-32)-NH<sub>2</sub> having the formula: H-Tyr-D-Ala-D-Asp-Ala-Ile-Phe-Thr-Asn-Ser-C<sup>a</sup>MeTyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-CMA-Arg-Lys-Leu-CML-Gln-Asp-Ile-CML-Ser-Arg-Gln-Gln-Gly-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as in Example 1. This analog is judged to be substantially pure using TLC and HPLC.

- 20 -

EXAMPLE 19

The synthesis of [D-Tyr<sup>1</sup>, D-NMA<sup>2</sup>, CML<sup>5</sup>, Lys<sup>8</sup>, C<sup>a</sup>Me-D-Tyr<sup>10</sup>, Ala<sup>15</sup>, D-Met<sup>27</sup>]-hGRF(1-29)-NH<sub>2</sub> having the formula: H-D-Tyr-D-NMA-Asp-Ala-CML-Phe-Thr-  
5 Lys-Ser-C<sup>a</sup>Me-D-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-D-Met-Ser-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as in Example 1. This analog is judged to be substantially pure using TLC  
10 and HPLC.

EXAMPLE 20

The synthesis of [D-His<sup>1</sup>, D-NMA<sup>2</sup>, Arg<sup>8</sup>, Leu<sup>13</sup>, CMA<sup>19</sup>, CML<sup>27</sup>]-rGRF(1-32)-NH<sub>2</sub> having the formula: H-D-His-D-NMA-Asp-Ala-Ile-Phe-Thr-Arg-  
15 Ser-Tyr-Arg-Arg-Leu-Leu-Gly-Gln-Leu-Tyr-CMA-Arg-Lys-Leu-Leu-His-Glu-Ile-CML-Asn-Arg-Gln-Gln-Gly-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin, in the manner generally described in Example 1. The peptide is judged  
20 to be substantially pure using TLC and HPLC.

EXAMPLE 21

The synthesis of a rGRF analog fragment i.e. [desaminoTyr<sup>1</sup>, CML<sup>23</sup>]-rGRF(1-29)-NH<sub>2</sub> having the formula: desNH<sub>2</sub>Tyr-Ala-Asp-Ala-Ile-Phe-Thr-  
25 Ser-Ser-Tyr-Arg-Arg-Ile-Leu-Gly-Gln-Leu-Tyr-Ala-Arg-Lys-Leu-CML-His-Glu-Ile-Met-Asn-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as in Example 1. The peptide is judged to be substantially pure using TLC and HPLC.

30

EXAMPLE 22

The synthesis of [Ac-D-Tyr<sup>1</sup>, D-NMA<sup>2</sup>, C<sup>a</sup>MeTyr<sup>10</sup>, C<sup>a</sup>MeVal<sup>13</sup>, CMA<sup>19</sup>, CML<sup>23</sup>, Nle<sup>27</sup>]-hGRF(1-29)-NH<sub>2</sub> having the formula: Ac-D-Tyr-D-NMA-Asp-Ala-Ile-Phe-Thr-  
35 Asn-Ser-C<sup>a</sup>MeTyr-Arg-Lys-C<sup>a</sup>MeVal-Leu-Gly-Gln-Leu-Ser-CMA-Arg-Lys-Leu-CML-Gln-Asp-Ile-Nle-Ser-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as generally

- 21 -

described in Vale et al. U.S. Patent No. 4,292,313. The peptide is judged to be substantially pure using TLC and HPLC.

#### EXAMPLE 23

5           The synthesis of [CML<sup>1</sup>, D-NMA<sup>2</sup>, Glu<sup>8</sup>, CMA<sup>19</sup>, Glu<sup>25</sup>, CML<sup>27</sup>]-rGRF(1-29)-NH<sub>2</sub> having the formula:  
H-CML-D-NMA-Asp-Ala-Ile-Phe-Thr-Glu-Ser-Tyr-Arg-Arg-Ile-Leu-Gly-Gln-Leu-Tyr-CMA-Arg-Lys-Leu-Leu-His-Glu-Ile-CML-Asn-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a  
10 Beckman 990 Peptide Synthesizer on an MBHA resin as in Example 1. The peptide is judged to be substantially pure using TLC and HPLC.

#### EXAMPLE 24

15           The synthesis of [For-D-Tyr<sup>1</sup>, D-NMA<sup>2</sup>, C<sup>a</sup>MeVal<sup>13</sup>, CMA<sup>19</sup>, Arg<sup>21</sup>, CML<sup>23</sup>, Asn<sup>28</sup>]-hGRF(1-29)-NH<sub>2</sub> having the formula: For-D-Tyr-D-NMA-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-C<sup>a</sup>MeVal-Leu-Gly-Gln-Leu-Ser-CMA-Arg-Arg-Leu-CML-Gln-Asp-Ile-Met-Asn-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer  
20 on an MBHA resin as generally described in Vale et al. U.S. Patent No. 4,292,313. The peptide is judged to be substantially pure using TLC and HPLC.

#### EXAMPLE 25

25           The synthesis of [NMA<sup>2</sup>, C<sup>a</sup>MeVal<sup>13</sup>, CML<sup>27</sup>]-hGRF(1-29)-NH<sub>2</sub> having the formula: H-Tyr-NMA-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-C<sup>a</sup>MeVal-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-CML-Ser-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as generally  
30 described in Vale et al. U.S. Patent No. 4,292,313. The peptide is judged to be substantially pure using TLC and HPLC. The acetate salt is then prepared by dissolving the peptide in water and adding 1N acetic acid. The resulting solution is lyophilized to yield the acetate  
35 salt.

- 22 -

EXAMPLE 26

The synthesis of the hGRF analog [D-NMA<sup>2</sup>, Arg<sup>8</sup>, CMA<sup>19</sup>, CML<sup>23</sup>, Nle<sup>27</sup>]-hGRF(1-32)-NH<sub>2</sub> having the formula: H-Tyr-D-NMA-Asp-Ala-Ile-Phe-Thr-Arg-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-CMA-Arg-Lys-Leu-CML-Gln-Asp-Ile-Nle-Ser-Arg-Gln-Gln-Gly-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as in Example 1. This analog is judged to be substantially pure using TLC and HPLC.

EXAMPLE 27

The synthesis of [CML<sup>17</sup>, Arg<sup>21</sup>, Nle<sup>27</sup>]-rGRF(1-29)-NH<sub>2</sub>, having the formula: H-His-Ala-Asp-Ala-Ile-Phe-Thr-Ser-Ser-Tyr-Arg-Arg-Ile-Leu-Gly-Gln-CML-Tyr-Ala-Arg-Arg-Leu-Leu-His-Glu-Ile-Nle-Asn-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as in Example 1. The peptide is judged to be substantially pure using TLC and HPLC.

EXAMPLE 28

The synthesis of the hGRF analog [D-NMA<sup>2</sup>, C<sup>a</sup>MeVal<sup>13</sup>, CMA<sup>19</sup>, CML<sup>23</sup>, Nle<sup>27</sup>, Asn<sup>28</sup>]-hGRF(1-29)-NH<sub>2</sub> having the formula: H-Tyr-D-NMA-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-C<sup>a</sup>MeVal-Leu-Gly-Gln-Leu-Ser-CMA-Arg-Lys-Leu-CML-Gln-Asp-Ile-Nle-Asn-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as in Example 1. The peptide is judged to be substantially pure using TLC and HPLC.

EXAMPLE 29

The synthesis of [N<sup>a</sup>MeTyr<sup>1</sup>, Ala<sup>15</sup>, CML<sup>26</sup>, Nle<sup>27</sup>, Asn<sup>28</sup>]-hGRF(1-29)-NH<sub>2</sub> having the formula: N<sup>a</sup>MeTyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Glu-CML-Nle-Asn-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as in Example 1. The peptide is judged to be substantially pure using TLC and HPLC. The optical rotation of the purified peptide is measured using a photoelectric



- 23 -

polorimeter and found to be  $[\alpha]_D = -43.5^\circ \pm 1$  (c = 1, 1% acetic acid).

#### EXAMPLE 30

The synthesis of [Met<sup>1</sup>, CMA<sup>19</sup>, Arg<sup>21</sup>, CML<sup>27</sup>]-rGRF(1-29)-NH<sub>2</sub> having the formula:  
H-Met-Ala-Asp-Ala-Ile-Phe-Thr-Ser-Ser-Tyr-Arg-Arg-Ile-Leu-Gly-Gln-Leu-Tyr-CMA-Arg-Arg-Leu-Leu-His-Glu-Ile-CML-Asn-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as in Example 1. The peptide is judged to be substantially pure using TLC and HPLC.

#### EXAMPLE 31

The synthesis of [pCl-Phe<sup>1</sup>, D-NMA<sup>2</sup>, C<sup>a</sup>MeTyr<sup>10</sup>, CMA<sup>19</sup>, Arg<sup>21</sup>, CML<sup>27</sup>]-rGRF(1-43)-OH having the formula: H-pCl-Phe-D-NMA-Asp-Ala-Ile-Phe-Thr-Ser-Ser-C<sup>a</sup>MeTyr-Arg-Arg-Ile-Leu-Gly-Gln-Leu-Tyr-CMA-Arg-Arg-Leu-Leu-His-Asp-Ile-CML-Asn-Arg-Gln-Gln-Gly-Glu-Arg-Asn-Gln-Glu-Gln-Arg-Ser-Arg-Phe-Asn-OH is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on a chloromethylated resin as in Example 3. The peptide is judged to be substantially pure using TLC and HPLC.

#### EXAMPLE 32

The synthesis of [N<sup>a</sup>MeTyr<sup>1</sup>, Ala<sup>15</sup>, CML<sup>23</sup>, Nle<sup>27</sup>, Asn<sup>28</sup>]-hGRF(1-29)-NH<sub>2</sub> having the formula:  
N<sup>a</sup>MeTyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Glu-Ile-Nle-Asn-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as in Example 1. The peptide is judged to be substantially pure using TLC and HPLC. The optical rotation of the purified peptide is measured using a photoelectric polorimeter and found to be  $[\alpha]_D = -44.0^\circ \pm 1$  (c = 1, 1% acetic acid).

#### EXAMPLE 33

The synthesis of [N<sup>a</sup>MeTyr<sup>1</sup>, CML<sup>13</sup>, Ala<sup>15</sup>, CML<sup>27</sup>, Asn<sup>28</sup>]-hGRF(1-29)-NH<sub>2</sub> having the formula:

- 24 -

N<sup>a</sup>MeTyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-CML-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Glu-Ile-CML-Asn-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as in  
 5 Example 1. The peptide is judged to be substantially pure using TLC and HPLC.

EXAMPLE 34

The synthesis of [N<sup>a</sup>MeTyr<sup>1</sup>, Ala<sup>15</sup>, CMA<sup>19</sup>, Nle<sup>27</sup>, Asn<sup>28</sup>]-hGRF(1-29)-NH<sub>2</sub> having the formula:  
 10 N<sup>a</sup>MeTyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-CMA-Arg-Lys-Leu-Leu-Gln-Glu-Ile-Nle-Asn-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as in  
 15 Example 1. The peptide is judged to be substantially pure using TLC and HPLC. The optical rotation of the purified peptide is measured using a photoelectric polarimeter and found to be  $[\alpha]_D = -45.5^\circ \pm 1$  (c = 1, 1% acetic acid).

EXAMPLE 35

The synthesis of [N<sup>a</sup>MeTyr<sup>1</sup>, Ala<sup>15</sup>, CML<sup>17</sup>, Nle<sup>27</sup>, Asn<sup>28</sup>]-hGRF(1-29)-NH<sub>2</sub> having the formula:  
 20 N<sup>a</sup>MeTyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-CML-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Glu-Ile-Nle-Asn-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a  
 25 Beckman 990 Peptide Synthesizer on an MBHA resin as in Example 1. The peptide is judged to be substantially pure using TLC and HPLC. The optical rotation of the purified peptide is measured using a photoelectric  
 30 polarimeter and found to be  $[\alpha]_D = 49.0^\circ \pm 1$  (c = 1, 1% acetic acid).

EXAMPLE 36

The synthesis of [N<sup>a</sup>MeTyr<sup>1</sup>, Ala<sup>15</sup>, CML<sup>23</sup>, Nle<sup>27</sup>, Asn<sup>28</sup>]-hGRF(1-29)-NH<sub>2</sub> having the formula:  
 35 N<sup>a</sup>MeTyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-CML-Gln-Glu-Ile-Nle-Asn-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as in

- 25 -

Example 1. The peptide is judged to be substantially pure using TLC and HPLC.

EXAMPLE 37

5 The synthesis of [ $N^a$ MeTyr<sup>1</sup>, CML<sup>5</sup>, Ala<sup>15</sup>, Nle<sup>27</sup>, Asn<sup>28</sup>]-hGRF(1-29)-NH<sub>2</sub> having the formula:  
N<sup>a</sup>MeTyr-Ala-Asp-Ala-CML-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-  
Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Glu-Ile-Nle-  
Asn-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a  
Beckman 990 Peptide Synthesizer on an MBHA resin as in  
10 Example 1. The peptide is judged to be substantially pure using TLC and HPLC. The optical rotation of the purified peptide is measured using a photoelectric polarimeter and found to be  $[\alpha]_D = -45.0^\circ \pm 1$  (c = 1, 1% acetic acid).

EXAMPLE 38

15 The synthesis of [ $N^a$ MeTyr<sup>1</sup>, CML<sup>5,13,17,22,27</sup>, Ala<sup>15</sup>, CMA<sup>19</sup>, Asn<sup>28</sup>]-hGRF(1-29)-NH<sub>2</sub> having the formula:  
N<sup>a</sup>MeTyr-Ala-Asp-Ala-CML-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-CML-  
Leu-Ala-Gln-CML-Ser-CMA-Arg-Lys-CML-Leu-Gln-Glu-Ile-CML-  
20 Asn-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as in Example 1. The peptide is judged to be substantially pure using TLC and HPLC.

EXAMPLE 39

25 The synthesis of [ $N^a$ MeTyr<sup>1</sup>, Ala<sup>15</sup>, CML<sup>22,27</sup>, Asn<sup>28</sup>]-hGRF(1-29)-NH<sub>2</sub> having the formula:  
N<sup>a</sup>MeTyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-  
Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-CML-Leu-Gln-Glu-Ile-CML-  
Asn-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a  
30 Beckman 990 Peptide Synthesizer on an MBHA resin as in Example 1. The peptide is judged to be substantially pure using TLC and HPLC.

EXAMPLE 40

35 The synthesis of [ $N^a$ MeTyr<sup>1</sup>, Ala<sup>15</sup>, CMA<sup>19</sup>, CMA<sup>23</sup>, Nle<sup>27</sup>, Asn<sup>28</sup>]-hGRF(1-29)-NH<sub>2</sub> having the formula:  
N<sup>a</sup>MeTyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-  
Leu-Ala-Gln-Leu-Ser-CMA-Arg-Lys-Leu-CML-Gln-Glu-Ile-Nle-

- 26 -

Asn-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as in Example 1. The peptide is judged to be substantially pure using TLC and HPLC.

5

EXAMPLE 41

The synthesis of [N<sup>a</sup>MeTyr<sup>1</sup>, Ala<sup>15</sup>, CML<sup>17,22,27</sup>, CMA<sup>19</sup>, Asn<sup>28</sup>]-hGRF(1-29)-NH<sub>2</sub> having the formula:

N<sup>a</sup>MeTyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-CML-Ser-CMA-Arg-Lys-CML-Leu-Gln-Glu-Ile-CML-

10

Asn-Arg-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as in Example 1. The peptide is judged to be substantially pure using TLC and HPLC.

EXAMPLE 42

15

The synthesis of a 40-residue amidated peptide [C<sup>a</sup>MeHis<sup>1</sup>, D-NMA<sup>2</sup>, CML<sup>27</sup>]-hGRF(1-44)-NH<sub>2</sub> having the formula: H-C<sup>a</sup>MeHis-D-NMA-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-CML-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH<sub>2</sub> is conducted in a stepwise manner using a Beckman 990 Peptide Synthesizer on an MBHA resin as generally described in Vale et al. U.S. Patent No. 4,292,313. The peptide is judged to be substantially pure using TLC and HPLC.

20

25

The synthetic peptides prepared in the Examples are compared with synthetic hpGRF(1-40)-OH in in vitro assays and are found to exhibit generally greater potencies for the secretion of GH and similar intrinsic activities. All of these synthetic peptides are considered to be biologically active and potentially useful for stimulating the release of GH by the pituitary.

30

35

To determine the relative effectiveness of certain representative synthetic peptides to promote the release of growth hormone, in vitro assays are carried out using synthetic hpGRF(1-40)-OH as a standard in side-by-side comparison with equimolar concentrations of

- 27 -

the representative analogs which have been synthesized. Cultures are used which include cells of rat pituitary glands removed some three to five days previously. Such cultures are considered optimal for the secretion of growth hormone and are used for the comparative testing, in the general manner described in Vale et al. Endocrinology, 91, 562-572 (1972) and as more particularly described in Vale et al. Endocrinology, 112, 1553-1555 (1983). Incubation with the substance to be tested is carried out for 3 to 4 hours, and aliquots of the culture medium are removed and processed to measure their contents in immunoreactive GH(ir GH) by a well-characterized radioimmunoassay.

The results of this comparative testing for equimolar concentrations are shown in Table I.

TABLE I

	<u>Peptide</u>	<u>In Vitro Potencies</u>
	hGRF(1-40)-OH	
	(standard for this test)	1.0
20	[N <sup>a</sup> MeTyr <sup>1</sup> , Ala <sup>15</sup> , CML <sup>27</sup> , Asn <sup>28</sup> ]-hGRF(1-29)-NH <sub>2</sub> .	10.00(5.2-20.1)
	[N <sup>a</sup> MeTyr <sup>1</sup> , Ala <sup>15</sup> , CML <sup>26</sup> , Nle <sup>27</sup> , Asn <sup>28</sup> ]-hGRF(1-29)-NH <sub>2</sub> .	6.44(4.0-10.3)
	[N <sup>a</sup> MeTyr <sup>1</sup> , Ala <sup>15</sup> , CML <sup>23</sup> , Nle <sup>27</sup> , Asn <sup>28</sup> ]-hGRF(1-29)-NH <sub>2</sub> .	1.96(1.1-3.3)
25	[N <sup>a</sup> MeTyr <sup>1</sup> , Ala <sup>15</sup> , CML <sup>17</sup> , Nle <sup>27</sup> , Asn <sup>28</sup> ]-hGRF(1-29)-NH <sub>2</sub> .	5.41(3.5-8.3)
	[N <sup>a</sup> MeTyr <sup>1</sup> , CML <sup>5</sup> , Ala <sup>15</sup> , Nle <sup>27</sup> , Asn <sup>28</sup> ]-hGRF(1-29)-NH <sub>2</sub> .	3.59(2.3-5.5)

In addition to the in vitro tests for secretion of growth hormone, in vivo experiments inject the synthetic peptides intravenously into urethane-anesthetized male rats and determine that they suppress spontaneous GH secretion without abolishing the response to exogenous GRF. Blood samples are taken immediately prior to, and 10, 30 and 60 minutes after injections, and GH levels in blood are measured by radioimmunoassay.

- 28 -

This in vivo testing of these synthetic peptides shows that each has greater biological potency than that exhibited by hpGRF(1-40)-OH and has substantially longer duration of effectiveness, which is shown in blood levels of pituitary GH when measured at both 30 and 60 min. after IV injection. Other known GRF in vivo tests that are known to be effective to detect secretion of GH are used to confirm these results. Dosages between about 500 nanograms and about 50 micrograms of these peptides per Kg. of body weight are considered to be effective in causing GH secretion.

Such synthetic hGRF analogs and possibly rGRF analogs should be useful for human applications in which a physician wishes to elevate GH production. Stimulation of GH secretion by such analogs is of interest in patients with complete or relative GH deficiency caused by underproduction of endogenous GRF. Furthermore, it is probable that increased GH secretion and its attendant increase in growth could be obtained in humans or animals with normal GH levels. Moreover, administration should alter body fat content and modify other GH-dependent metabolic, immunologic and developmental processes. For example, these analogs may be useful as a means of stimulating anabolic processes in human beings under circumstances such as following the incurring of burns. As another example, these analogs may be administered to commercial warm-blooded animals, such as chickens, turkeys, pigs, goats, cattle and sheep, and may be used in aquiculture for raising fish and other cold-blooded marine animals, e.g. sea turtles and eels, and amphibians, to accelerate growth and increase the ratio of protein to fat gained by feeding effective amounts of the peptides.

For administration to humans, these synthetic peptides should have a purity of at least about 93% and preferably at least 98%. Purity, for purposes of this application, refers to the intended peptide constituting

- 29 -

the stated weight % of all peptides and peptide fragments present. For the administration of such synthetic peptides to commercial and other animals in order to promote growth and reduce fat content, lower purities may  
5 be acceptable.

These synthetic peptides or the nontoxic salts thereof, combined with a pharmaceutically or veterinarily acceptable carrier to form a pharmaceutical composition, may be administered to animals, including humans, either  
10 intravenously, subcutaneously, intramuscularly, percutaneously, e.g. intranasally or even orally. The administration may be employed by a physician to stimulate the release of GH where the host being treated requires such therapeutic treatment. The required dosage  
15 will vary with the particular condition being treated, with the severity of the condition and with the duration of desired treatment.

Such peptides are often administered in the form of nontoxic salts, such as acid addition salts or metal  
20 complexes, e.g., with zinc, iron or the like (which are considered as salts for purposes of this application). Illustrative of such acid addition salts are hydrochloride, hydrobromide, sulphate, phosphate, maleate, acetate, citrate, benzoate, succinate, malate,  
25 ascorbate, tartrate and the like. If the active ingredient is to be orally administered in tablet form, the tablet may contain a binder, such as tragacanth, corn starch or gelatin; a disintegrating agent, such as alginic acid; and a lubricant, such as magnesium  
30 stearate. If administration in liquid form is desired, sweetening and/or flavoring may be used, and intravenous administration in isotonic saline, phosphate buffer solutions or the like may be effected.

The peptides should be administered to humans  
35 under the guidance of a physician, and pharmaceutical compositions will usually contain the peptide in conjunction with a conventional, solid or liquid,

- 30 -

pharmaceutically-acceptable carrier. Usually, the parenteral dosage will be from about 0.01 to about 1 microgram of the peptide per kilogram of the body weight of the host.

5           It may also be desirable to deliver such a peptide over prolonged periods of time, for example, for periods of one week to one year from a single administration, and slow release, depot or implant dosage forms may be utilized. For example, a dosage form may  
10 contain a pharmaceutically acceptable non-toxic salt of the compound which has a low degree of solubility in body fluids, for example, an acid addition salt with the polybasic acid; a salt with a polyvalent metal cation; or combination of the two salts. A relatively insoluble  
15 salt may also be formulated in a gel, for example, an aluminum stearate gel. A suitable slow release depot formulation for injection may also contain the peptide or a salt thereof dispersed or encapsulated in a slow  
20 degrading, non-toxic or non-antigenic polymer, such as a polylactic acid/polyglycolic acid polymer, for example, as described in U.S. Pat. No. 3,773,919. These compounds may also be formulated into silastic implants.

          It is also possible to administer the peptides transdermally to humans over an extended period of time  
25 using electrical current, as reported in Meyer, B.R. et al., Clin. Pharm. & Therapeutics, 44, 6, 607-612 (1988). For example, transdermal patches can be used which utilize a 9-volt battery to continuously apply  
30 about 0.2 milliamp current to human skin and which hereby effectively deliver the peptides through the epidermis into the bloodstream.

          Although the invention has been described with regard to its preferred embodiments, which constitute the best mode presently known to the inventors, it should be  
35 understood that various changes and modifications as would be obvious to one having the ordinary skill in this art may be made without departing from the scope of the



- 31 -

invention which is set forth in the claims appended hereto. For example, modifications in the peptide chain, particularly deletions beginning at the carboxyl terminus of the peptide and extending to about position-29, can be made in accordance with the known experimental practises to date to create peptides or peptide fragments that retain all or very substantial portions of the biological potency of the peptide, and such peptides are considered as being within the scope of the invention. Moreover, additions may be made to either terminus, or to both terminals, and/or generally equivalent residues can be substituted for naturally occurring residues, as is well-known in the overall art of peptide chemistry, to produce other analogs having at least a substantial portion of the potency of the claimed polypeptide without deviating from the scope of the invention. Moreover, modifications may be made to the preferred  $\text{-NH}_2$  group at the C-terminus in accordance with the state of this art today; for example, the carboxyl moiety of the amino acid residue at the C-terminus can be the radical  $\text{-COOR}$ ,  $\text{-CRO}$ ,  $\text{-CONHNHR}$ ,  $\text{-CON(R)(R')}$  or  $\text{-CH}_2\text{OR}$ , with R and R' being lower alkyl, fluoro lower alkyl or hydrogen, without deviating from the invention for such modifications result in equivalent synthetic peptides.

Various features of the invention are emphasized in the claims which follow.

- 32 -

## CLAIMS:

1. A synthetic peptide having the formula:  
 5 [N<sup>a</sup>MeTyr<sup>1</sup>, Ala<sup>15</sup>, CML<sup>23</sup>, Nle<sup>27</sup>, Asn<sup>28</sup>]-hGRF(1-29)-NH<sub>2</sub>;  
 [N<sup>a</sup>MeTyr<sup>1</sup>, Ala<sup>15</sup>, CMA<sup>17</sup>, Nle<sup>27</sup>, Asn<sup>28</sup>]-hGRF(1-29)-NH<sub>2</sub>;  
 [N<sup>a</sup>MeTyr<sup>1</sup>, Ala<sup>15</sup>, CML<sup>26</sup>, Nle<sup>27</sup>, Asn<sup>28</sup>]-hGRF(1-29)-NH<sub>2</sub>;  
 or [N<sup>a</sup>MeTyr<sup>1</sup>, Ala<sup>15</sup>, CML<sup>27</sup>, Asn<sup>28</sup>]-hGRF(1-29)-NH<sub>2</sub>.

2. A synthetic peptide, or a nontoxic salt  
 thereof, having the sequence: (B)R<sub>1</sub>-R<sub>2</sub>-R<sub>3</sub>-Ala-  
 10 (Q<sub>1</sub>)R<sub>5</sub>-Phe-Thr-R<sub>8</sub>-Ser-(Q<sub>2</sub>)R<sub>10</sub>-Arg-R<sub>12</sub>-(Q<sub>3</sub>)R<sub>13</sub>-Leu-  
 R<sub>15</sub>-Gln-(Q<sub>4</sub>)Leu-R<sub>18</sub>-(Q<sub>5</sub>)Ala-Arg-R<sub>21</sub>-(Q<sub>6</sub>)R<sub>22</sub>-(Q<sub>7</sub>)Leu-  
 R<sub>24</sub>-R<sub>25</sub>-(Q<sub>8</sub>)R<sub>26</sub>-(Q<sub>9</sub>)R<sub>27</sub>-R<sub>28</sub>-Arg-Gln-Gln-Gly-Glu-R<sub>34</sub>-  
 Asn-Gln-Glu-R<sub>38</sub>-R<sub>39</sub>-R<sub>40</sub>-Arg-R<sub>42</sub>-R<sub>43</sub>-R<sub>44</sub> wherein R<sub>1</sub> is Tyr,  
 D-Tyr, Met, Phe, D-Phe, pCl-Phe, Leu, His or D-His; B is  
 15 H, C<sup>a</sup>Me, N<sup>a</sup>Me, desamino, Ac or For; R<sub>2</sub> is Ala,  
 D-Ala, NMA or D-NMA; R<sub>3</sub> is Asp or D-Asp; R<sub>5</sub> is Ile or  
 Leu; R<sub>8</sub> is Ser, Asn, Lys, Arg, Asp or Glu; R<sub>10</sub> is  
 Tyr, D-Tyr or Phe; R<sub>12</sub> is Arg or Lys; R<sub>13</sub> is Ile,  
 Val, Leu or Ala; R<sub>15</sub> is Gly or Ala; R<sub>18</sub> is Ser or  
 20 Tyr; R<sub>21</sub> is Lys, D-Lys, Arg or D-Arg; R<sub>22</sub> is Leu,  
 Ile, Ala or Val; R<sub>24</sub> is Gln or His; R<sub>25</sub> is Asp or  
 Glu; R<sub>26</sub> is Ile or Leu; R<sub>27</sub> is Met, D-Met, Ala, Nle,  
 Ile, Leu, Nva or Val; R<sub>28</sub> is Asn or Ser; R<sub>34</sub> is Ser  
 or Arg; R<sub>38</sub> is Arg or Gln; R<sub>39</sub> is Gly or Arg; R<sub>40</sub>  
 25 is Ala or Ser; R<sub>42</sub> is Phe, Ala or Val; R<sub>43</sub> is Asn or  
 Arg; R<sub>44</sub> is a natural amino acid; Q<sub>1</sub>-Q<sub>9</sub> are either  
 H or C<sup>a</sup>Me, provided however that any or all of the  
 residues between R<sub>30</sub> and R<sub>44</sub>, inclusive, may be  
 deleted in a sequence beginning at the C-terminus, and  
 30 provided also that at least one of Q<sub>1</sub>, Q<sub>4</sub>, Q<sub>7</sub>, Q<sub>8</sub>  
 and Q<sub>9</sub> is C<sup>a</sup>Me.

3. The peptide of Claim 2 wherein R<sub>27</sub> is Nle  
 and residues 30 through 44 are deleted.

4. The peptide of Claim 2 wherein R<sub>15</sub> is Ala  
 35 and R<sub>28</sub> is Asn.

5. The peptide of Claim 2 wherein Q<sub>1</sub> is C<sup>a</sup>Me.

6. The peptide of Claim 2 wherein Q<sub>4</sub> is C<sup>a</sup>Me.

- 33 -

7. The peptide of Claim 2 wherein Q<sub>7</sub> is C<sup>a</sup>Me.

8. The peptide of Claim 2 wherein Q<sub>8</sub> is C<sup>a</sup>Me.

9. The peptide of Claim 2 wherein Q<sub>9</sub> is C<sup>a</sup>Me.

10. A synthetic peptide, or a nontoxic salt thereof, having the formula:

(B)R<sub>1</sub>-R<sub>2</sub>-Asp-Ala-(Q<sub>1</sub>)Ile-Phe-Thr-R<sub>8</sub>-Ser-(Q<sub>2</sub>)R<sub>10</sub>-Arg-R<sub>12</sub>-(Q<sub>3</sub>)R<sub>13</sub>-Leu-R<sub>15</sub>-Gln-(Q<sub>4</sub>)Leu-R<sub>18</sub>-(Q<sub>5</sub>)Ala-Arg-R<sub>21</sub>-(Q<sub>6</sub>)R<sub>22</sub>-(Q<sub>7</sub>)Leu-R<sub>24</sub>-R<sub>25</sub>-(Q<sub>8</sub>)R<sub>26</sub>-(Q<sub>9</sub>)R<sub>27</sub>-R<sub>28</sub>-Arg-Gln-Gln-Gly-Y

wherein R<sub>1</sub> is Tyr, D-Tyr, Phe, D-Phe, His or D-His;

10 B is H, C<sup>a</sup>Me or N<sup>a</sup>Me; R<sub>2</sub> is Ala, D-Ala, NMA or D-NMA; R<sub>8</sub> is Ser, Asn, Lys, Arg, Asp or Glu; R<sub>10</sub> is Tyr, D-Tyr or Phe; R<sub>12</sub> is Arg or Lys; R<sub>13</sub> is Ile, Val, Leu or Ala; R<sub>15</sub> is Gly or Ala; R<sub>18</sub> is Ser or Tyr; R<sub>21</sub> is Lys, D-Lys, Arg or D-Arg; R<sub>22</sub> is Leu, Ile, Ala or Val; R<sub>24</sub> is

15 Gln or His; R<sub>25</sub> is Asp or Glu; R<sub>27</sub> is Met, Ala, Nle, Ile, Leu, Nva or Val; R<sub>28</sub> is Asn or Ser; Y is NHR with R being H or lower alkyl; Q<sub>1</sub>-Q<sub>9</sub> are either H or C<sup>a</sup>Me, provided however that Gly, Gln-Gly or Gln-Gln-Gly may be deleted at the C-terminus, and provided also that at least one of Q<sub>1</sub>,

20 Q<sub>4</sub>, Q<sub>7</sub>, Q<sub>8</sub> and Q<sub>9</sub> is C<sup>a</sup>Me.

# INTERNATIONAL SEARCH REPORT

International Application No PCT/US 90/02224

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup> According to International Patent Classification (IPC) or to both National Classification and IPC IPC <sup>5</sup> : C 07 K 7/10, A 61 K 37/43		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
IPC <sup>5</sup>	C 07 K, A 61 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b>		
Category <sup>9</sup>	Citation of Document, <sup>11</sup> with Indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	EP, A, 0216517 (THE SALK INSTITUTE FOR BIOLOGICAL STUDIES) 1 April 1987 see the whole document --	2-4,10
X	EP, A, 0292334 (THE SALK INSTITUTE FOR BIOLOGICAL STUDIES) 23 November 1988 see the whole document -----	2-4,10
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search 31st July 1990		Date of Mailing of this International Search Report 14. 09. 90
International Searching Authority EUROPEAN PATENT OFFICE		Signature of Authorized Officer <div style="display: flex; align-items: center; justify-content: center;"> <div style="margin-right: 10px;"><i>M. Peis</i></div> <div style="border: 1px solid black; padding: 2px 5px;">M. PEIS</div> </div>

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND ~~TO BE~~ <sup>incompletely</sup> SEARCHABLE <sup>1</sup>

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers ..... because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☒ Claim numbers 2, 10 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  

Claims 2 and 10 are so general, that the general search is impossible. The search has been restricted to the remaining claims.
3. ☐ Claim numbers ..... because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING <sup>2</sup>

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

## Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9002224  
SA 36772

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on 07/09/90  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0216517	01-04-87	US-A- 4689318	25-08-87
		AU-B- 589674	19-10-89
		AU-A- 6183886	05-03-87
		JP-A- 62051698	06-03-87
EP-A- 0292334	23-11-88	AU-A- 1647788	24-11-88
		JP-A- 1009999	13-01-89
		ZA-A- 8802832	11-11-88